Literature DB >> 22541999

Male acquired hypogonadotropic hypogonadism: diagnosis and treatment.

Sylvie Salenave1, Sévérine Trabado, Luigi Maione, Sylvie Brailly-Tabard, Jacques Young.   

Abstract

Acquired hypogonadotropic hypogonadism (AHH), contrary to congenital hypogonadotropic hypogonadism (CHH) is characterized by postnatal onset of disorders that damage or alter the function of gonadotropin-releasing hormone (GnRH) neurons and/or pituitary gonadotroph cells. AHH thus prevents the establishment of gonadotropin secretion at puberty, or its post-pubertal maintenance. Thus, postnatal AHH may prevent the onset of puberty or appear during pubertal development, but it usually emerges after the normal age of puberty. Although pituitary tumors, particularly prolactinoma, are the most common cause, sellar tumors or cyst of the hypothalamus or infundibulum, infiltrative, vascular, iron overload and other disorders may also cause AHH. Pituitary surgery and head trauma or cranial/pituitary radiation therapy are also usual causes of AHH. The clinical manifestations of AHH depend on age of onset, the degree of gonadotropin deficiency, the rapidity of its onset and the association to other pituitary function deficiencies or excess. Men with AHH have less stamina, decreased libido, erectile dysfunction and strength, and a worsened sense of well being leading to degraded quality of life. The physical examination is usually normal if hypogonadism is of recent onset. Diminished facial, body hair and muscle mass, fine facial wrinkles, gynecomastia, and hypotrophic testes are observed in long-standing and complete AHH. Spermatogenesis is impaired and the volume of ejaculate is decreased only when gonadotropins and testosterone levels are very low. Men with AHH may have normal or low serum LH and FSH concentrations, but normal gonadotropin values are inappropriate when associated with low serum testosterone. In the majority of AHH patients, serum inhibin B is "normal". The decrease of this sertolian hormone indicates a long-standing and severe gonadotropin deficiency. Symptoms, usually associated with significant testosterone deficiency in men with AHH, improve with testosterone replacement therapy. Replacement therapy is often simple, using an injectable testosterone ester as first line treatment. Fertility can be restored rather quickly, provided there is no independent primary testicular damage and the partner is fertile.
Copyright © 2012. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541999     DOI: 10.1016/j.ando.2012.03.040

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  8 in total

1.  Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors.

Authors:  Ralph E Vatner; Andrzej Niemierko; Madhusmita Misra; Elizabeth A Weyman; Claire P Goebel; David H Ebb; Robin M Jones; Mary S Huang; Anita Mahajan; David R Grosshans; Arnold C Paulino; Takara Stanley; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2018-08-17       Impact factor: 44.544

2.  Nonsurgical Management of Oligozoospermia.

Authors:  Jeremy T Choy; John K Amory
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

Review 3.  The Impact of Intense Exercise on Semen Quality.

Authors:  Paweł Jóźków; Marco Rossato
Journal:  Am J Mens Health       Date:  2016-09-19

4.  Acquired Hypogonadotropic Hypogonadism (AHH) in Thalassaemia Major Patients: An Underdiagnosed Condition?

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Alessia Pepe; Christos Kattamis; Nada A Soliman; Rania Elalaily; Mohamed El Kholy; Mohamed Yassin
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-01-01       Impact factor: 2.576

5.  Endocrine profile of β-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center.

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Nada A Soliman; Rania Elalaily; Christos Kattamis
Journal:  Indian J Endocrinol Metab       Date:  2016 Jul-Aug

6.  Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism.

Authors:  Jianli Lin; Jiangfeng Mao; Xi Wang; Wanlu Ma; Ming Hao; Xueyan Wu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 7.  Follicle-stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles.

Authors:  Daniele Santi; Pascale Crépieux; Eric Reiter; Giorgia Spaggiari; Giulia Brigante; Livio Casarini; Vincenzo Rochira; Manuela Simoni
Journal:  J Clin Med       Date:  2020-04-03       Impact factor: 4.241

Review 8.  FSH for the Treatment of Male Infertility.

Authors:  Livio Casarini; Pascale Crépieux; Eric Reiter; Clara Lazzaretti; Elia Paradiso; Vincenzo Rochira; Giulia Brigante; Daniele Santi; Manuela Simoni
Journal:  Int J Mol Sci       Date:  2020-03-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.